DarioHealth DRIO 深 滬
等待開盤 10-28 09:30:00 美东时间
3.48
+0.080
+2.35%
華盛通- 最 高3.55
- 今 開3.55
- 成交量 4.41万股
- 最 低 3.21
- 昨 收 3.40
- 總市值 3410.22万
- 52周最高 14.77
- 市盈率 靜 --
- 換手率 0.45%
- 52周最低 3.01
- 委 比 0.50%
- 總股本 979.95万
- 歷史最高 1697760.00
- 量 比 0.28
- 振 幅 10.00%
- 歷史最低 3.01
- 每 手 1
- 風險率 2.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅94.81%！富瑞上调ArriVent BioPharma(AVBP)目标价至30美元，维持"买入"评级
今日重点评级关注：富瑞：维持ArriVent BioPharma"买入"评级，目标价从18美元升至30美元；古根海姆：维持第一太阳能"买入"评级，目标价从282美元升至299美元
今天 12:30
DarioHealth Expands Contract With Dario To Add Dario Women, Recently Launched Women's Health Solution Supporting Women Navigating Perimenopause And Menopause Symptoms
Contract extension follows benefits realized from Dario's cardiometabolic program and strong employee demand for perimenopause support Nearly 45% of Dario's current book of business is women over age 40 who could potentially benefit from Dario Women™ Dario's expanding multi-condition platform addres...
10-26 20:38
DarioHealth Secures New Jersey Health Plan Contract Through Amwell Partnership; Dario's Cardiometabolic Suite Launch Set For Q1 2027
Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategy Program for Dario's cardiometabolic suite and provider-backed care expected to launch with the customer and begin generating revenue in the first quarter of 2027 Marks the t...
09-17 19:36
美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
Alliance Global Partners Initiates Coverage On DarioHealth with Buy Rating, Announces Price Target of $12
Alliance Global Partners analyst Scott Henry initiates coverage on DarioHealth (NASDAQ:DRIO) with a Buy rating and announces Price Target of $12.
08-19 23:45
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
TD Cowen Maintains Hold on DarioHealth, Lowers Price Target to $8
TD Cowen analyst Charles Rhyee maintains DarioHealth (NASDAQ:DRIO) with a Hold and lowers the price target from $11 to $8.
08-12 23:17
DarioHealth Q2 Adj. EPS $(0.72) Beats $(1.22) Estimate, Sales $5.177M Miss $5.923M Estimate
DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.22) by 40.98 percent. This is a 82.44 percent increase over losses of $(4.10) per share from the same period last year. The company reported quarterly sales of $5.177 million whi...
08-11 18:33
DarioHealth 2026财年第二季度业绩：尽管营收下滑但利润率扩大
DarioHealth（NASDAQ: DRIO）公布2026财年第二季度营收为520万美元，低于上年同期的540万美元，主因是公司减少了部分与制药相关的业务。毛利率从55.2%提升至61.7%，营业费用下降21%，GAAP营业亏损收窄至650万美元。截至6月底，公司持有的现金、现金等价物及短期存款约为1400万美元，随后在7月净融资2280万美元。新增的多病种服务合同及客户拓展预计将在2026年晚些时候开始贡献业绩，并在2027年带来更显著的成效。
08-11 10:43
DarioHealth Q2 2026 earnings: Margin expands despite lower revenue
DarioHealth (NASDAQ: DRIO) reported Q2 2026 revenue of $5.2 million, down from $5.4 million a year earlier as it moved away from certain pharmaceutical-related work. Gross margin rose to 61.7% from 55.2%, while operating expenses fell 21% and the GAAP operating loss narrowed to $6.5 million. The company ended June with about $14.0 million in cash, equivalents and short-term deposits, then raised $22.8 million net in July. New multi-condition cont
08-11 10:42
